Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Anuo Youda Gene Technology (Beijing) Co., Ltd. to provide supplementary materials regarding the cancellation of certain subsidiaries and the progress of obtaining qualifications for various IVD products and services [1][2]. Group 1: Company Operations - Anuo Youda is required to explain the reasons and progress for the cancellation of Zhejiang Anuo Youda, Anwei Kang Technology, and Yiwu Inspection Institute, and whether this has a significant adverse impact on the company's business [2]. - The company is involved in the development and commercialization of IVD products based on molecular diagnostics, focusing on non-invasive prenatal testing (NIPT) kits, sequencing instruments, and bioinformatics analysis software [6]. - Anuo Youda's NIPT kits, which detect the three most common chromosomal diseases (trisomy 21, 18, and 13), received Class III medical device certification in 2017, establishing the company as one of the early leaders in the prenatal testing market in China [7]. Group 2: Market Position - According to Zhi Shi Consulting, Anuo Youda ranked third in the NIPT market in China by sample testing volume in 2023, with market shares increasing by 9.6%, 11.6%, and 12.1% in 2021, 2022, and 2023, respectively [7]. - The company's clinical sequencing solutions include self-developed IVD testing kits and related services, with clients primarily consisting of hospitals certified for prenatal diagnosis and independent medical laboratories [6]. Group 3: Regulatory Compliance - The CSRC has requested clarification on the company's compliance with foreign investment restrictions and whether its business operations align with the necessary qualifications and regulatory requirements [2][5]. - Anuo Youda must also address any administrative penalties related to violations of the Cybersecurity Law of the People's Republic of China and the progress of any required rectifications [4].

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 据 IPO早知道消息，矽电半导体设备(深圳)股份有限公司（以下简称"矽电股份"）于2025年3月24 日正式以"301629"为股票代码在深交所创业板挂牌上市。 成立于 2003年的矽电股份专注于半导体探针测试技术领域，主要产品为探针台设备，是中国大陆规 模最大的探针台设备制造企业。同时，作为中国最早研发探针测试技术的企业之一，矽电股份也是中 国大陆首家实现产业化应用的12英寸晶圆探针台设备厂商，已在多个半导体产品领域打破海外厂商 垄断。 这里不妨补充一点，探针测试技术主要应用于半导体制造晶圆检测 (CP, Circuit Probing)环节，也 应用于全流程晶圆接受测试(WAT 测试, Wafer Acceptance Test)、设计验证和成品测试(FT, Final Test)环节，是检测芯片性能与缺陷，保证芯片测试准确性，提高芯片测试效率的关键技术。 目前，矽电股份自主研发了多种类型应用探针测试技术的半导体设备，产品已广泛应用于集成电路、 光电芯片、分立器件、第三代化合物半导体等半导体产品制造领域，其探针测试系列产品已应用于士 兰微、比 ...